How is Doxil used in multiple myeloma?
For the treatment of myeloma, Doxil is typically used together with other anticancer agents. Doxil is often used in place of conventional doxorubicin, and it is also used as part of novel combination therapies. Doxil is approved by the FDA for use in combination with Velcade to treat patients with myeloma who have not previously received Velcade and have received at least one prior therapy. Results of clinical trials show that that adding Doxil to a standard Velcade regimen reduced the risk of the disease progressing and prolonged the duration of response in patients with relapsed and refractory disease better than Velcade alone. Doxil is being studied in combination with other approved myeloma drugs and in combination with new drugs in development for the treatment of relapsed and/or refractory myeloma. Doxil is also being studied as part of combination therapies for the treatment of newly diagnosed or previously untreated myeloma, also referred to as frontline therapy.
